Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue SUPPL. 2, 2008, Pages

  Osada, Taro ^a   Ohkusa, Toshifumi ^a   Okayasu, Isao ^b   Yoshida, Tsutomu ^b   Hirai, Shu ^a   Beppu, Kazuko ^a   Shibuya, Tomoyoshi ^a   Sakamoto, Naoto ^a   Kobayashi, Osamu ^a   Nagahara, Akihito ^a   Terai, Takeshi ^a   Watanabe, Sumio ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Clinical activity; Clinical symptoms; Laboratory markers; Total colonoscopy; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; GLUCOCORTICOID; MESALAZINE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE;

ADULT; AGED; CLINICAL FEATURE; COLON INJURY; COLONOSCOPY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOCYTE COUNT; ULCERATIVE COLITIS;

EID: 57449093379     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05413.x     Document Type: Conference Paper

References (29)

1. Chutkan RK, Waye JD. Endoscopy in inflammatory bowel disease. In : Kirsner JB, ed. Inflammatory Bowel Disease, 5th edn. Baltimore : Williams & Wilkins, 2000 453 77.
2. Cohen T, Pfeffer RB, Valensi Q. 'Ulcerative appendicitis' occurring as a skip lesion in chronic ulcerative colitis; report of a case. Am. J. Gastroenterol. 1974 62 : 151 5.
3. Yamagishi N, Iizuka B, Nakamura T, Suzuki S, Hayashi N. Clinical and colonoscopic investigation of skipped periappendiceal lesions in ulcerative colitis. Scand. J. Gastroenterol. 2002 37 : 177 82.
4. Matsumoto T, Nakamura S, Shimizu M, Iida M. Significance of appendiceal involvement in patients with ulcerative colitis. Gastrointest. Endosc. 2002 55 : 180 5.
5. Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986 27 : 809 13.
6. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955 29 : 1041 8.
7. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand. J. Gastroenterol. 1978 13 : 833 7.
8. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am. J. Gastroenterol. 1992 87 : 971 6.
9. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998 43 : 29 32.
10. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 1994 330 : 1841 5.
11. Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin. Gastroenterol. Hepatol. 2005 3 : 11 24.
12. Korelitz BI, Sommers SC. Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes. Am. J. Gastroenterol. 1975 64 : 365 70.
13. Floren CH, Benoni C, Willen R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand. J. Gastroenterol. 1987 22 : 459 62.
14. Fochios SE, Korelitz BI. The role of sigmoidoscopy and rectal biopsy in diagnosis and management of inflammatory bowel disease: personal experience. Am. J. Gastroenterol. 1988 83 : 114 19.
15. Higgins PD, Schwartz M, Mapili J, Zimmermann EM. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am. J. Gastroenterol. 2005 100 : 355 61.
16. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006 55 : 749 53.
17. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N. Engl. J. Med. 1987 317 : 1625 9.
18. Sandborn WJ, Tremaine WJ, Schroeder KW et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994 106 : 1429 35.
19. Seo M, Okada M, Maeda K et al. Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. Am. J. Gastroenterol. 1998 93 : 2124 9.
20. Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard-Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig. Dis. Sci. 1982 27 : 533 7.
21. Gomes P, du Boulay CD, Smith CL, Holdstock G. Relationship between disease indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986 27 : 92 5.
22. Fagan EA, Dyck RF, Maton PN et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur. J. Clin. Invest. 1982 12 : 351 9.
23. Tall AR. C-reactive protein reassessed. N. Engl. J. Med. 2004 350 : 1450 2.
24. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999 340 : 448 54.
25. Matts SGF. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q. J. Med. 1961 120 : 393 407.
26. Bernstein CN, Shanahan F, Anton PA, Weinstein WM. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. Gastrointest. Endosc. 1995 42 : 232 7.
27. D'Haens G, Geboes K, Peeters M, Baert F, Ectors N, Rutgeerts P. Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am. J. Gastroenterol. 1997 92 : 1275 9.
28. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991 32 : 174 8.
29. Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004 126 : 451 9.